kras

Pancreatic cancer's undruggable wall just cracked. The follow-up is 8.5 months and the money was already placed.

Revolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.